title: Bladder cancers respond to EGFR inhibitors.
abstract: Researchers have discovered that nearly 25% of muscle-invasive bladder cancers fall into a "basal-like" subgroup that overexpresses EGFR and other proteins in the same pathway. EGFR inhibitors like erlotinib and cetuximab are effective against basal-like cell lines and tumors implanted into mice, arguing for clinical trials of the drugs for patients with this cancer subtype.
mesh_terms: D000818:Animals; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009132:Muscles / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy*
chemical_list: D066246:ErbB Receptors